An experimental drug cuts genetic heart disease risk by 94% in trial: What we know

An experimental drug cuts genetic heart disease risk by 94% in trial: What we know

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a mid-stage clinical trial involving 141 patients. Lp(a) is a genetic risk factor for heart attacks, strokes and aortic valve narrowing, affecting 1.4 billion people globally. Unlike LDL cholesterol, Lp(a) cannot be managed through diet or statins, and no approved treatments exist

Eli Lilly logo is shown on one of the company’s offices in San Diego, California, US, September 17, 2020. File Image/Reuters